Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, a clinical stage biotech company developing novel oncolytic immunotherapies, has announced its participation in two upcoming investor conferences. The company's management team will host investor meetings at the BTIG Virtual Biotechnology Conference on August 5-6, 2024, and the 2024 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2024.
These conferences provide Replimune with opportunities to engage with investors and showcase their progress in developing innovative cancer treatments. As a Nasdaq-listed company (REPL), Replimune's participation in these events may be of interest to current and potential investors in the biotechnology sector.
Replimune Group, una azienda biotecnologica in fase clinica che sviluppa nuove immunoterapie oncolitiche, ha annunciato la propria partecipazione a due prossime conferenze per investitori. Il team di gestione dell'azienda ospiterà incontri con gli investitori alla Conferenza Virtuale sulla Biotecnologia BTIG il 5-6 agosto 2024, e alla Conferenza Wedbush PacGrow sulla Sanità 2024 martedì 13 agosto 2024.
Queste conferenze offrono a Replimune opportunità di interagire con gli investitori e di mostrare i loro progressi nello sviluppo di trattamenti innovativi per il cancro. Essendo una società quotata al Nasdaq (REPL), la partecipazione di Replimune a questi eventi potrebbe suscitare interesse tra gli investitori attuali e potenziali nel settore biotecnologico.
Replimune Group, una empresa biotecnológica en etapa clínica que desarrolla nuevas inmunoterapias oncolíticas, ha anunciado su participación en dos próximas conferencias para inversores. El equipo de gestión de la empresa llevará a cabo reuniones con inversores en la Conferencia Virtual de Biotecnología de BTIG el 5-6 de agosto de 2024, y en la Conferencia de Salud Wedbush PacGrow 2024 el martes 13 de agosto de 2024.
Estas conferencias ofrecen a Replimune oportunidades para interactuar con los inversores y mostrar su progreso en el desarrollo de tratamientos innovadores para el cáncer. Como empresa cotizada en Nasdaq (REPL), la participación de Replimune en estos eventos puede ser de interés para los inversores actuales y potenciales en el sector biotecnológico.
Replimune Group는 새로운 종양리시스 면역요법을 개발하는 임상 단계의 생명공학 회사로, 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 회사의 경영진은 2024년 8월 5일부터 6일 사이에 열리는 BTIG 가상 생명공학 회의와 2024년 8월 13일 화요일에 열리는 Wedbush PacGrow 의료 회의에서 투자자 회의를 주최할 예정입니다.
이 회의들은 Replimune에게 투자자와 소통하고 혁신적인 암 치료법 개발의 진척을 보여줄 수 있는 기회를 제공합니다. 나스닥 상장 기업(티커: REPL)인 Replimune의 이러한 행사 참여는 생명공학 분야의 현재 및 잠재적 투자자들에게 관심을 끌 수 있습니다.
Replimune Group, une entreprise biopharmaceutique en phase clinique développant de nouvelles immunothérapies oncolytiques, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'équipe de direction de l'entreprise organisera des réunions investisseurs lors de la Conférence Virtuelle sur la Biotechnologie de BTIG les 5 et 6 août 2024, ainsi qu'à la Conférence 2024 Wedbush PacGrow sur les Soins de Santé le mardi 13 août 2024.
Ces conférences offrent à Replimune des opportunités d'interagir avec les investisseurs et de présenter ses progrès dans le développement de traitements innovants contre le cancer. En tant qu'entreprise cotée au Nasdaq (REPL), la participation de Replimune à ces événements pourrait intéresser les investisseurs actuels et potentiels du secteur biotechnologique.
Replimune Group, ein biopharmazeutisches Unternehmen in der klinischen Phase, das neuartige onkolytische Immuntherapien entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Management-Team des Unternehmens wird Investorenmeetings auf der BTIG Virtuellen Biotechnologiekonferenz am 5.-6. August 2024 und der 2024 Wedbush PacGrow Gesundheitskonferenz am Dienstag, den 13. August 2024, veranstalten.
Diese Konferenzen bieten Replimune die Möglichkeit, mit Investoren zu interagieren und ihre Fortschritte bei der Entwicklung innovativer Krebsbehandlungen zu präsentieren. Als am Nasdaq gelistetes Unternehmen (REPL) könnte die Teilnahme von Replimune an diesen Veranstaltungen für aktuelle und potenzielle Investoren im Bereich Biotechnologie von Interesse sein.
- None.
- None.
WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will host investor meetings at the following two conferences:
BTIG Virtual Biotechnology Conference
Dates: August 5-6, 2024
2024 Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 13, 2024
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
What investor conferences will Replimune (REPL) attend in August 2024?
What type of company is Replimune (REPL)?
When is Replimune (REPL) participating in the Wedbush PacGrow Healthcare Conference?
What is the stock symbol for Replimune?
